This post is presented by our media partner Psychedelic News Wire
View the original article here.
Psychedelics have enjoyed significant public interest in recent years due to their purported medical benefits. As more regions in the United States and across the world loosened psychedelic restrictions, initial research on psychedelics found that these substances could treat various mental disorders with fewer side effects.
This initial research opened the flood and led to the investment of millions of dollars into psychedelic research worldwide. Continued research has revealed that several psychedelics can be effective against a multitude of mental disorders, offering sustained and long-term relief at relatively minimal doses.
Scientists have been especially interested in how psychedelics affect brain chemistry and allow people to leave depressive states. Although most psychedelic research is still in its infancy, it has been found that psychedelic-assisted therapy, or the combination of psychedelics and talk therapy, is the most effective at treating mental conditions.
New research has found that LSD triggers changes in the brain by changing the effects of brain stimulation, allowing the psychedelic to produce various effects on an even larger scale. The research suggests that hallucinogenics could be used to develop various novel ways of treating a laundry list of health conditions.
One way that psychedelics deliver their benefits is by inducing neuroplasticity. This refers to the brain’s ability to reorganize and create new neural connections in response to stimuli. Psychedelics also induce changes by interacting with the serotonin 2A receptor to influence perception, cognition and mood.
The combination of enhancing neuroplasticity and interacting with receptors in the brain may be the reason why psychedelics provide long-term relief against conditions such as anxiety, depression and PTSD.
Lucas Dwiel, a study author and postdoctoral fellow at the Doucette Lab at the Geisel School of Medicine at Dartmouth, explained that while conventional treatments such as transcranial magnetic stimulation (TMS) may be effective against a wide range of psychiatric conditions, they rarely provide long-term relief. Dwiel said that using psychedelics such as LSD to make the brain easily susceptible to change would prolong the relief period and make psychiatric treatment more effective for plenty of patients.
His research team used rat models to measure changes in brain activity after administering LSD and analyzed the effects of combining LSD with brain stimulation. The team found that stimulating the brain 24 hours after administering a dose of LSD resulted in a state where the brain was susceptible to external interventions. Their results indicate that LSD may play a role in causing brain changes that come to the fore when the brain is stimulated.
Further studies are needed to fully understand the connection between LSD and brain stimulation, and this connection could be used to develop novel psychedelic treatments.
Further studies are also being conducted by various psychedelic industry players such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) to establish other ways through which these substances can be leveraged to treat a variety of conditions, including major depressive disorder.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
This post was originally published by our media partner here.